(08 Sep 2020) Tocilizumab- effective in managing early CRS related to COVID-19 disease

Tocilizumab for severe COVID-19 related illness – A community academic medical center experience

https://doi.org/10.1016/j.cytox.2020.100035

In an academic community medical center,31 patients with anti-IL-6/IL-6-R agents including 12 who had already been intubated were treated with TCZ. Overall, 27 (87%) patients are alive and 24 (77%) have been discharged from the hospital. Clinical responses to anti-IL-6/IL-6-R therapy were accompanied by significant decreases in temperature, oxygen requirement, CRP, IL-6, and IL-10 levels. Based on these data, we believe anti-IL-6/IL-6-R therapy can be effective in managing early CRS related to COVID-19 disease.